A systematic review of the effectiveness of policies restricting access to pregabalin

BACKGROUND: Formularies often employ restriction policies to reduce pharmacy costs. Pregabalin, an alpha-2-delta ligand, is approved for treatment of fibromyalgia (FM); neuropathic pain (NeP) due to postherpetic neuralgia (PHN), diabetic peripheral neuropathy (pDPN), spinal cord injury; and as adjun...

Descripción completa

Detalles Bibliográficos
Autores principales: Stacey, Brett R., Liss, Jonathan, Behar, Regina, Sadosky, Alesia, Parsons, Bruce, Masters, Elizabeth T., Hlavacek, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389065/
https://www.ncbi.nlm.nih.gov/pubmed/28841868
http://dx.doi.org/10.1186/s12913-017-2503-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389065/
https://www.ncbi.nlm.nih.gov/pubmed/28841868
http://dx.doi.org/10.1186/s12913-017-2503-x

Ejemplares similares